Dr.PhD.sc. David E. Martin izlaganje kod Dr. sc. Reiner Füllmicha_sa Prevodom_Serb_Cro❤👁❤

Speakers: David E. Martin, PhD
Dr. David Martin is the founding CEO of M∙CAM Inc. M∙CAM is the international leader in intellectual property-based financial risk management. From auditing patent quality for governments and patent offices, to providing state-of-the-art actuarial risk management systems and solutions to the largest banks and insurance companies, M∙CAM has established a global standard in patent quality and commercial validity assessment and management.

A spokesperson for global intellectual property accountability and quality reform, Dr. Martin has worked closely with the United States Congress, numerous trade and finance regulatory agencies in the United States, Europe and Asia, in advocating and deploying infrastructure to support growing reliance on proprietary rights in business transactions. M∙CAM has supported the modernization of intellectual property, tax, and accounting laws through its work with oversight agencies and policy makers.

Dr. Martin has founded several for-profit and non-profit companies and organizations and serves of several boards. He was the founding CEO of Mosaic Technologies Inc., a company that developed and commercialized advanced computational linguistics technologies, dynamic data compression and encryption technologies, electrical field transmission technology, medical diagnostics, and stealth/anechoic technology. He was a founding member of Japan’s Institute for Interface Science & Technology. He founded and served as Executive Director of the Charlottesville Venture Group. He has served as a board member for the Research Institute for Small and Emerging Business (Washington D.C.), the Academy for Augmenting Grassroots Technological Innovations (India), the IST (Japan) the Charlottesville Regional Chamber of Commerce (Virginia), and the Charlottesville Industrial Development Agency (Virginia).

As former Assistant Professor at the University of Virginia’s School of Medicine, Dr. Martin founded the University’s first wholly-owned, for-profit, research and development and technology transfer corporation. Engaged in domestic and international technology transfer, clinical research, and financing, this company pioneered new techniques innovation management that have become industry standards. In 1999, Dr. Martin was appointed by the Governor of the Commonwealth of Virginia to serve on the Joint Commission on Technology and Science and has served the General Assembly and Virginia’s Center for Innovative Technology on numerous occasions.

Dr. Martin’s work with the Batten Institute at the Darden Graduate School of Business Administration at the University of Virginia and his related work at the Indian Institute for Management in Ahmedabad India has brought unprecedented curricular focus to areas of intangible asset risk management, finance, and accounting standards. In addition to his academic work, Dr. Martin has closely advised intellectual property based finance and investment programs in India, China, Denmark, the European Union, the United Kingdom, South Africa, the Islamic Republic of Iran, the United States, and the United Arab Emirates.

Dr. Martin has publications in law, medicine, engineering, finance and education. He maintains active research in the fields of linguistic genomics, fractal financial risk modeling, as well as continuing his over 15 years of research in cellular membrane ionic signaling.

O činjenicama s poznatim njemačkim odvjetnikom Dr. sc. Reiner Füllmichom govori svjetski stručnjak iz područja patentnog prava Dr. sc. David E. Martin koji se preko 20 godina bavi patentima, njihovim istraživanjima i praćenjem na svjetskoj razini. Na koji je način to u uskoj vezi s pandemijom COVIDA-19, pogledajte sami. Unatoč tome što je već prilično upoznat s problematikom oko lažiranja pandemije, pregledom patenata i ulaganja u iste ostao je šokiran u kojoj mjeri je organizirana hobotnica različitih interesa, koja djeluje sinkronizirano u cijeloj ovoj priči.

Pored toga za svaku tvrdnju koju Dr. sc. Martin navodi u video snimci, prilažemo reference s izvorima gdje se dokazi za iste mogu pronaći.

* Vrijeme Link

1 0:00 https://www.wipo.int/meetings/en/2006/scp_of_ge_06/speakers/martin.html

2 0:00 https://corona-ausschuss.de/en/

3 0:14 https://www.m-cam.com/

4 2:33 https://www.m-cam.com/2020/04/03/sars-cov-patent-corpus-literature-review/

5 2:54 https://talk.ictvonline.org/

6 2:54 https://www.who.int/

7 5:25 https://patft.uspto.gov/netacgi/nph-Parser

8 5:55 https://sph.unc.edu/adv_profile/ralph-s-baric-phd/

9 5:55 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131501/

10 6:47 https://www.niaid.nih.gov/

11 7:13 https://www.unc.edu/

12 8:13 https://patft.uspto.gov/netacgi/nph-Parser

13 10:04 https://www.nih.gov/

14 10:09 https://www.usamriid.army.mil/

15 11:35 https://www.cdc.gov/

16 11:56 https://www.uspto.gov/web/offices/pac/mpep/s2104.html

17 12:10 https://patft.uspto.gov/netacgi/nph-Parser

18 12:30 https://patents.google.com/patent/US7220852B1/e

19 12:40 https://patft.uspto.gov/netacgi/nph-Parser

20 17:14 https://www.crunchbase.com/organization/sequoia-pharmaceuticals

21 17:48 https://www.ablynx.com/

22 18:20 https://patft.uspto.gov/netacgi/nph-Parser

23 19:19 https://www.justice.gov/archives/jm/criminal-resource-manual-109-rico-charges

24 20:09 https://www.darpa.mil/

25 20:44 https://www.news-medical.net/health/What-is-a-Polybasic-Cleavage-Site.aspx

26 20:50 https://www.news-medical.net/health/What-is-a-Receptor-Binding-Domain-(RBD).aspx

27 21:09 https://patft.uspto.gov/netacgi/nph-Parser

28 21:21 https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers

29 21:50 https://www.devex.com/organizations/crucell-44661

30 21:50 https://johnsonandjohnson.gcs-web.com/news-releases/news-release-details/johnson-johnson-acquires-9889-issued-crucell-shares-end/

31 21:50 https://www.rubiustx.com/

32 21:55 https://www.childrenshospital.org/

33 22:03 https://www.lmu.de/de/index.html

34 22:08 https://en.wikipedia.org/wiki/Protein_Sciences

35 22:08 https://www.dana-farber.org/

36 22:12 https://uiowa.edu/

37 22:12 https://www.hku.hk/

38 22:14 http://www.chgc.sh.cn/

39 22:14 https://www.bionity.com/en/research-institutes/73756/chinese-national-human-genome-centre-cnhg.html

40 24:56 https://www.ecohealthalliance.org/personnel/dr-peter-daszak

41 25:05 https://www.quotes.net/quote/85355

42 25:05 https://www.nap.edu/search/?year=2016&rpp=20&ft=1&term=peter+daszak

43 26:25 https://blogs.bmj.com/bmj/2021/01/04/peter-doshi-pfizer-and-modernas-95-effective-vaccines-we-need-more-details-and-the-raw-data/

44 26:57 https://en.wikipedia.org/wiki/Red_herring

45 27:46 https://drexel.edu/research/innovation/technology-commercialization/bayh-dole-act/

46 27:46 https://en.wikipedia.org/wiki/Bayh%E2%80%93Dole_Act

47 29:37 https://pubmed.ncbi.nlm.nih.gov/15057645/

48 29:56 https://apps.who.int/gpmb/

49 29:59 http://www.chinacdc.cn/en/aboutus/leadership/201603/t20160324_128015.html

50 30:04 https://www.gatesfoundation.org/

51 31:47 http://www.arbutusbio.com/

52 31:47 https://acuitastx.com/

53 39:16 https://www.niaid.nih.gov/about/vrc

54 42:54 https://www.fda.gov/

55 43:34 https://uni-bielefeld.de/fakultaeten/rechtswissenschaft/ls/schwab/

56 46:21 http://www.beggarscanbechoosers.com/2007/06/wingnuts-denounce-tin-foil-hat-liberals.html

57 47:33 https://www.healthline.com/health/r-nought-reproduction-number

58 47:44 https://www.gisaid.org/

59 56:41 https://www.wipo.int/portal/en/index.html

60 1:00:02 https://en.wikipedia.org/wiki/Christian_Drosten

61 1:00:02 https://www.charite.de/en/

62 1:01:25 https://www.tib-molbiol.de/

63 1:01:25 https://www.bloomberg.com/news/articles/2020-03-12/a-berlin-biotech-company-got-a-head-start-on-coronavirus-tests

64 1:01:31 https://www.cdc.gov/zika/prevention/index.html

65 1:06:51 https://www.bundestag.de/ausschuesse/weitere_gremien/enquete_ki

66 1:07:19 https://www.epo.org/

67 1:09:36 https://www.investopedia.com/terms/r/regulatory-capture.asp

68 22:32 https://www.sciencedirect.com/science/article/pii/S096098222030662X

Zanimljive činjenice o kojima je govorio Dr. David E. Martin (zabunio se u vezi datuma kod patenta #7220852 jer master filing date nije 23.04.2003. već 28.04.2003., vidi ispod)

25.04.2003. (plaćeno da prijava ostane tajna)

#7220852, master filing date, virus (CDC)

28.04.2003. (prijavljuje se cjepivo za virus samo 3 dana poslije, a prijava je tajna)

#7151163, master filing date, cjepivo (Sequoia Pharmaceuticals)

19.12.2006. (patent na cjepivo odobren 5 mjeseci prije samog virusa za koje je to cjepivo proizvedeno)

#7151163, patent approval date, cjepivo (Sequoia Pharmaceuticals)

22.05.2007.

#7220852, patent approval date, virus (CDC)